WO2006005951A1 - Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof - Google Patents

Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof Download PDF

Info

Publication number
WO2006005951A1
WO2006005951A1 PCT/GB2005/002744 GB2005002744W WO2006005951A1 WO 2006005951 A1 WO2006005951 A1 WO 2006005951A1 GB 2005002744 W GB2005002744 W GB 2005002744W WO 2006005951 A1 WO2006005951 A1 WO 2006005951A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxamide
dibenz
azepine
dihydro
hydroxy
Prior art date
Application number
PCT/GB2005/002744
Other languages
French (fr)
Inventor
David Alexander Learmonth
Günter WEINGAERTNER
Matthias Kraemer
Original Assignee
Portela & C.A. S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK05759707T priority Critical patent/DK1789395T3/en
Priority to CA2574002A priority patent/CA2574002C/en
Priority to EP05759707A priority patent/EP1789395B8/en
Priority to BRPI0513383-1A priority patent/BRPI0513383A/en
Priority to DE602005012405T priority patent/DE602005012405D1/en
Priority to AU2005261497A priority patent/AU2005261497A1/en
Application filed by Portela & C.A. S.A. filed Critical Portela & C.A. S.A.
Priority to MX2007000575A priority patent/MX2007000575A/en
Priority to JP2007520888A priority patent/JP2008506676A/en
Priority to US11/572,077 priority patent/US7999100B2/en
Priority to PL05759707T priority patent/PL1789395T3/en
Publication of WO2006005951A1 publication Critical patent/WO2006005951A1/en
Priority to HR20090212T priority patent/HRP20090212T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • a key step in the synthesis of either of the optically pure individual acetate esters (V) or (Vl) involves the resolution of racemic ( ⁇ )-10,11 ⁇ dihydro-10-hydroxy-5H ⁇ dibenz/b,f/azepine-5-carboxamide (III) into its individual, optically pure stereoisomers, (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) and (R)-(-)- 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II), which are the principal intermediates for synthesis of the enantiomerically pure acetates (V) and (Vl).
  • the Mitsunobu procedure should preferably involve the use of readily available solvents and reagents, and be operationally simple whilst affording good yields of chirally-inverted, esterified products. Additionally, it would be highly desirable for large-scale manufacturing purposes to develop the Mitsunobu inversion reaction so as to obtain the desired inverted products in high purity and yield through a significantly simplified purification process without resort to inconvenient and tedious purification by column chromatography over .
  • the inverted products can be very easily isolated from the reaction mixture by evaporation of the reaction solvent, and replacement with a suitable crystallisation solvent such as for example, lower aliphatic alcohols such as methanol, ethanol or isopropanol, with or without addition of water, esters including ethyl acetate and isopropyl acetate or ketones including acetone and methyl ethyl ketone.
  • a suitable crystallisation solvent such as for example, lower aliphatic alcohols such as methanol, ethanol or isopropanol, with or without addition of water, esters including ethyl acetate and isopropyl acetate or ketones including acetone and methyl ethyl ketone.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A method for chiral inversion of optically pure or optically enriched mixtures of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) and (R)-(-)-10,11­dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) with a carboxylic acid nucleophile in the presence of a trisubstituted phosphine and a disubstituted azodicarboxylate in a substantially inert solvent is disclosed.

Description

B2005/002744
Method for chiral inversion of (SH+)- and (RH-H 0,11-dihydro-10-hvdroxy-5H- dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
This invention relates to a method for chiral inversion of optically pure or optically enriched mixtures of (S)-(+)-10,11~dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide and (R)-(-)-10,11~dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (compounds of formulas (I) and (II) respectively).
Racemic (±)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (III) has been shown to possess anti-convulsant activity (Schutz, H. et al., Xenobiotica, 16, 769- 778 (1986)), and is the principal metabolite of the established anti-epileptic drug oxcarbazepine (IV). This racemate (III) serves as a useful intermediate for the preparation of optically pure (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5- carboxamide (V) and (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5- carboxamide (formula Vl), two more recently disclosed, single-enantiomer putative anti- epileptic drugs demonstrating improved biological properties (Benes, J. et al., J. Med. Chem., 42, 2582-2587 (1999)). The (S)-(-)-enantiomer (V) in particular has been shown to display a very favourable anti-convulsant profile.
Figure imgf000002_0001
(I), R=H (II), R=H (Dl) (IV)
(V), R=COCH3 (Vl), R=COCH3
A key step in the synthesis of either of the optically pure individual acetate esters (V) or (Vl) involves the resolution of racemic (±)-10,11~dihydro-10-hydroxy-5H~ dibenz/b,f/azepine-5-carboxamide (III) into its individual, optically pure stereoisomers, (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) and (R)-(-)- 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II), which are the principal intermediates for synthesis of the enantiomerically pure acetates (V) and (Vl). An improved method for this resolution was recently disclosed involving the efficient separation of diastereoisomeric tartrate half-esters of racemic (+)-10,11-dihydro-10- hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (III) (Learmonth, D., PCT/GB02/02176).
Racemic (±)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (III) can be easily prepared by reduction of the ketone group of oxcarbazepine (IV), by the use of, for example, metal hydrides in alcoholic medium. However, oxcarbazepine (IV) is an expensive substance, and despite the very efficient resolution procedure (around 98% yield based on a single diastereoisomer), development of say only the (S)-(-)-acetate (V) would mean the loss of approximately 50% of costly material. It would thus be highly desirable to have a method of recycling this unwanted, but expensive (R)-(-)- 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) which can be recovered from the resolution mixture. However recycling of this material is very complicated due to the propensity for elimination of water across the C10-C11 junction even under very mild conditions, which provides an olefinic product of negligible economic interest. Notwithstanding, recycling could be envisaged to involve inversion of the chiral centre at C-10 by a Mitsunobu reaction protocol with concomitant esterification (Mitsunobu, O., Synthesis, 1-29, (1981 )), whereby the recovered but unwanted optically enriched (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) is converted directly to the (S)-(-)-acetate (V) or to analogous chirally inverted ester derivatives of potential biological interest. The Mitsunobu procedure should preferably involve the use of readily available solvents and reagents, and be operationally simple whilst affording good yields of chirally-inverted, esterified products. Additionally, it would be highly desirable for large-scale manufacturing purposes to develop the Mitsunobu inversion reaction so as to obtain the desired inverted products in high purity and yield through a significantly simplified purification process without resort to inconvenient and tedious purification by column chromatography over .silica gel which is usually required to remove unwanted reagents and by-products associated with the Mitsunobu reaction, such as, for example, triphenylphosphine, triphenylphosphine oxide, disubstituted azodicarboxylate and reduced hydrazine- derivatives thereof. It has now been found that the reaction of optically enriched (enantiomeric excesses in the range from 1 to 99.5%) (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) or (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (I) with a combination of a tri-substituted phosphine, a disubstituted azodicarboxylate and a carboxylic acid nucleophile in a suitably inert solvent gives good yields of chirally inverted esterified products, without significant formation of undesired olefinic products, which can be surprisingly easily separated from the further unwanted Mitsunobu reaction by-products by crystallisation from a suitable solvent without the need for chromatographic separation, giving the method of the present invention according to the following synthetic scheme:
opti
Figure imgf000004_0001
from (II) from (I)
According to the present invention, the C-10 chiral alcohol functionality of optically pure or optically-enriched (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) or (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (I) undergoes a chiral switch and concomitant esterification via a Mitsunobu reaction with suitable carboxylic acid nucleophiles, such as, for example, aliphatic, cyclic, aromatic or heteroaromatic carboxylic acids including formic acid, acetic acid, propionic acid, butyric acid, cyclohexanoic acid, optionally substituted benzoic acids, nicotinic acid and the like. The carboxylic acid nucleophile can be used in a 1.02-5 molar ratio with respect to the optically pure or enriched alcohol (I) or (II), but preferably in the range 1.05-2.2. The reaction is carried out using a redox combination of a tri-substituted phosphine and disubstituted azodicarboxylate. Typical phosphines which are useful in the reaction include tri-n-propylphosphine, tri-n- butylphosphine, triphenylphosphine, tri-o-tolylphosphine, diphenyl(2-pyridyl)phosphine, (4-dimethylamino)diphenylphosphine, tris(dimethylamino)phosphine and the like. If preferred, the tri-substituted phosphine can be supported on an inert polymer. Preferred disubstituted azodicarboxylates include dimethylazodicarboxylate, diethylazodicarboxylate, diisopropylazodicarboxylate, di-tert-butylazodicarboxylate, 1 ,1 '-(azodicarbonyl)dipiperidine and the like. Preferably, the tri-substituted phosphine and disubstituted azodicarboxylate are both used in equimolar quantities with respect to the optically pure or enriched alcohol (I) or (II). The reaction can be run in a solvent which is inert under the reaction conditions, such as, for example, chlorinated solvents including dichloromethane, chloroform and carbon tetrachloride, aliphatic or cyclic ethers including diethyl ether, tetrahydrofuran and dioxane, amides including dimethylformamide and hydrocarbons including toluene and the like. The reaction can be carried out over a wide range of temperatures, from -780C to the boiling point of the solvent used, but preferably in the range 0°C-30°C. The inverted products can be very easily isolated from the reaction mixture by evaporation of the reaction solvent, and replacement with a suitable crystallisation solvent such as for example, lower aliphatic alcohols such as methanol, ethanol or isopropanol, with or without addition of water, esters including ethyl acetate and isopropyl acetate or ketones including acetone and methyl ethyl ketone. The inverted product is then recovered by filtration and, if preferred, can be further purified by slurrying or recrystallisation from suitable solvents, such as, for example, lower aliphatic alcohols such as methanol, ethanol or isopropanol, with or without addition of water, esters including ethyl acetate or isopropyl acetate or ketones including acetone and methyl ethyl ketone. The optical purity of the inverted, esterified product can be easily determined by chiral HPLC analysis.
According to another aspect of the invention, there is provided a method for the preparation of a compound of the general formula (VIII):
Figure imgf000005_0001
where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 4 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms, preferably 5 or 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting optically pure or optically enriched (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) with the corresponding carboxylic acid nucleophile by a process as described above.
According to another aspect of the invention, there is provided a method for the preparation of a compound of the general formula (IX):
Figure imgf000006_0001
(IX) where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 4 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms, preferably 5 or 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting optically enriched (S)- (+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) with the corresponding carboxylic acid nucleophile by a process as described above. Resolution of the racemic (±)-10,11-dihydro~10-hydroxy~5H-dibenz/b,f/azepine-5- carboxamide (III) into its optically pure stereoisomers (S)-(+)-10,11-dihydro-10-hydroxy- 5H-dibenz/b,f/azepine-5-carboxamide (I) and (R)-(-)-10,11-dihydro-10-hydroxy-5H- dibenz/b,f/azepine-5-carboxamide (II) is possible as described in more detail in our application no. PCT/GB02/02176. The compounds of formulas (VIII) and (IX) are described in more detail in our US patent no. 5753646, the contents of which are incorporated herein by reference.
For example, under the present invention, it is now possible to produce (S)-(-)-10- acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (I) directly from (R)-(-)- 10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) of opposite stereochemical configuration, by chiral inversion and concomitant O-acetylation by reaction with acetic acid as nucleophile in the presence of diisopropylazodicarboxylate and triphenylphosphine in a solvent such as tetrahydrofuran.
The compounds described in examples 4 to 23 of US5753646 can be produced by chiral inversion and concomitant esterification using the appropriate carboxylic acid nucleophile. Using the present invention, it is therefore possible to produce all of the following compounds:
(1) 10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(2) 10-benzoyloxy-10, 11 -dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(3) 10-(4-methoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(4) 10-(3-methoxybenzoyloxy)-10,11 -dihydro-5H-dibenz/b,f/azepine-5-carboxamide (5) 10-(2-methoxybenzoloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(6) 10-(4-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(7) 10-(3-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(8) 10-(2-nitrobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(9) lO^-chlorobenzoyloxy^iO.H-dihydro-δH-dibenz/b.f/azepine-δ-carboxamide (10) 10-(3-chlorobenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(11) 10-(2-acetoxybenzoyloxy)-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(12) 10-propionyloxy-10, 11 -dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(13) 10-butyroyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (14) 10-pivaloyloxy-10,11 -dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(15) 10-[(2-propyl)pentanoyloxy]-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(16) 10-[(2-ethyl)hexanoyloxy]-10, 11 -dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(17) 10-stearoyloxy-10,11~dihydro-5H-dibenz/b,f/azepiπe-5-carboxamide (18) 10-cyclopentanoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(19) lO-cyclohexanoyloxy-IO.H-dihydro-δH-dibenz/b.f/azepine-δ-carboxamide
(20) 10-phenylacetoxy-10,11-dihydro-δH-bibenz/b,f/azepine-δ-carboxamide
(21) 10-(4-methoxyphenyl)acetoxy-10,11-dihydro-5H-dibenz/b,f/-azepine-5- carboxamide (22) 10-(3-methoxyphenyl)acetoxy-10, 11 -dihydro-5H-dibenz/b,f/azepine-5- carboxamide
(23) lO^-nitrophenyOacetoxy-IO.I I-dihydro-SH-dibenz/b.f/azepine-δ-carboxamide
(24) lO-^-nitrophenyOacetoxy-IO.I I-dihydro-δH-dibenz/b.f/azepine-δ-carboxamide
(25) lO-nicotinoyloxy-IO.H-dihydro-δH-dibenz/b.f/azepine-δ-carboxamide (26) 10-isonicotinoyloxy-10,11-dihydro-δH-dibenz/b,f/azepine-δ-carboxamide
(27) 10-formyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(28) 10-chloroacetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
(29) 10-bromoacetoxy-10,11-dihydro-δH-dibenz/b,f/azepine-δ-carboxamide
(30) 10-(2-chloropropionyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-δ-carboxamide
As already mentioned, optically pure or optically-enriched mixtures of both (R)-(-)-and (S)-(+)-10,11-dihydro-10-hydroxy-δH-dibenz/b,f/azepine-δ-carboxamide (III) can be inverted and esterified by the present invention, whereby the desired (R)-(+)- or (S)-(-)- stereoisomers of all of the above compounds may be produced.
These compounds, or pharmaceutically acceptable derivatives thereof (such as salts), can be used in the preparation of pharmaceutical compositions comprising the compound itself, or the derivative, in combination with a pharmaceutically acceptable carrier. Such compositions have anticonvulsant properties and can be used in the treatment of some central and peripheral nervous system disorders, such as epilepsy.
The invention disclosed herein is exemplified by the following examples of preparation. It is to be understood that the invention is not to be limited to the exact details of operation, as obvious modifications and equivalents will be apparent to those skilled in the art.
Example 1. (S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (V)
To a stirred suspension of (R)-(-)-10,11-dihydro-10-hydroxy~5H-dibenz/b,f/azepine-5- carboxamide (II) (1.0g, 3.94mmol) (98.85% optical purity by chiral HPLC analysis), triphenylphosphine (1.03g, 3.94mmol) and acetic acid (0.47g, 7.88mmol) in tetrahydrofuran (12ml_) cooled in an ice-water bath was added diisopropylazodicarboxylate (0.8Og, 3.94mmol) dropwise. After addition was complete, the reaction mixture, which became a cloudy yellow solution, was allowed to stir at room temperature for four hours, whereupon the tetrahydrofuran was evaporated (4O0C1 water-aspirator pressure), lsopropanol (5ml_) was added to the oily residue and the mixture was warmed to the boiling point of the solvent. The mixture was then allowed to cool to room temperature, and then stored at 50C for one hour. The precipitate was collected by filtration, and then recrystallised from isopropanol (4 mL). The crystals were collected by filtration and after drying to constant weight, there was obtained (S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (V) as white crystals (0.48g, 41 %) of m.p. 186-1870C.
Chiral HPLC analysis of this product (LiChroCART 250-4 HPLC Cartridge ChiraDex 5μm, (Merck), Flowrate: 0.8mL/min, Mobile Phase: 0.1 M Na2HPO4 buffer pH7/methanol 88:12, sample injected was 20μL of 0.2mg analyte/mL dissolved in the mobile phase, and UV detection at 210/254nm showed complete inversion and O-acetylation with 0.9% (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (Vi) with retention time 15.98 minutes and 99.2% (S)-(-)-10-acetoxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide (V) with retention time of 21.33 minutes.
Example 2. (S)-(-)-10-Butyroyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
To a stirred suspension of (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5~ carboxamide (II) (1.0g, 3.94mmol) (98.85% optical purity by chiral HPLC analysis), triphenylphosphine (1.03g, 3.94mmol) and butyric acid (0.69g, 7.88mmol) in tetrahydrofuran (12mL) cooled in an ice-water bath was added diisopropylazodicarboxylate (0.8Og, 3.94mmol) dropwise. After addition was complete, the reaction mixture, which became a yellow solution, was allowed to stir at room temperature for two hours, whereupon the tetrahydrofuran was evaporated (4O0C, 5 water-aspirator pressure), lsopropanol (5mL) was added to the oily residue and the mixture was warmed to the boiling point of the solvent. The mixture was then allowed to cool to room temperature, and then stored at 5°C for one hour. The precipitate was collected by filtration, and then recrystallised from isopropanol (4 mL). The crystals were collected by filtration and after drying to constant weight, there was obtained (S)-(- 10 )-10-butyroyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide as white crystals (0.57g, 45%) of m.p. 173-1750C.
Chiral HPLC analysis of this product (LiChroCART 250-4 HPLC Cartridge ChiraDex 5μm, (Merck), Flowrate: 0.8mL/min, Mobile Phase: 0.1 M Na2HPO4 buffer pH7/methanol
15 88:12, sample injected was 20μL of 0.2mg analyte/mL dissolved in the mobile phase, and UV detection at 210/254nm showed complete inversion and esterification with 0.6% (R)-(+)-10-butyroyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide with retention time 19.65 minutes and 99.4% (S)-(-)-10-butyroyloxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide with retention time of 22.61 minutes. 0
Example 3. (S)-(-)-10-Benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide
To a stirred suspension of (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) (1.0g, 3.94mmol) (98.85% optical purity by chiral HPLC analysis), 5 triphenylphosphine (1.03g, 3.94mmol) and benzoic acid (0.96g, 7.88mmol) in tetrahydrofuran (12mL) cooled in an ice-water bath was added diisopropylazodicarboxylate (0.8Og, 3.94mmol) dropwise. After addition was complete, the reaction mixture, which became a yellow solution, was allowed to stir at room temperature for two hours, whereupon the tetrahydrofuran was evaporated (400C, 0 water-aspirator pressure). Isopropanol (5mL) was added to the oily residue and the mixture was warmed to the boiling point of the solvent. The mixture was then allowed to cool to room temperature, and then stored at 50C for one hour. The precipitate was collected by filtration, and then recrystallised from isopropanol (4 mL). The crystals were collected by filtration and after drying to constant weight, there was obtained (S)-(- )-10-benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide as white crystals (0.68g, 48%) of m. p. 167-1710C.
Chiral HPLC analysis of this product (LiChroCART 250-4 HPLC Cartridge ChiraDex 5μm, (Merck), Flowrate: 0.8mL/min, Mobile Phase: 0.1 M Na2HPO4 buffer pH7/methano! 88:12, sample injected was 20μL of 0.2mg analyte/mL dissolved in the mobile phase, and UV detection at 210/254nm showed complete inversion and esterification with 21% (R)-(+)-10-benzoyloxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide with retention time 42.61 minutes and 78% (S)-(-)-10-benzoyloxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide with retention time of 45.4 minutes.
Example 4. (S)-(-)-10,11-Dihydro-10-nicotinoyloxy-5H-dibenz/b,f/azepine-5- carboxamide
To a stirred suspension of (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) (1.0g, 3.94mmol) (98.85% optical purity by chiral HPLC analysis), triphenylphosphine (1.03g, 3.94mmol) and nicotinic acid (0.97g, 7.88mmol) in tetrahydrofuran (12mL) cooled in an ice-water bath was added diisopropylazodicarboxylate (0.8Og, 3.94mmol) dropwise. After addition was complete, the reaction mixture, which became a yellow solution, was allowed to stir at room temperature for two hours, whereupon the tetrahydrofuran was evaporated (400C, water-aspirator pressure), lsopropanol (5mL) was added to the oily residue and the mixture was warmed to the boiling point of the solvent. The mixture was then allowed to cool to room temperature, and then stored at 50C for one hour. The precipitate was collected by filtration, and then recrystallised from isopropanol (4 mL). The crystals were collected by filtration and after drying to constant weight, there was obtained lO.H-dihydro-IO-nicotinoyloxy-δH-dibenz/b.f/azepine-δ-carboxamide as white crystals (0.47g, 34%) of m.p. 167-17O0C.
Chiral HPLC analysis of this product (LiChroCART 250-4 HPLC Cartridge ChiraDex 5μm, (Merck), Flowrate: 0.8mL/min, Mobile Phase: 0.1 M Na2HPO4 buffer pH7/methanol 88:12, sample injected was 20μL of 0.2mg analyte/mL dissolved in the mobile phase, and UV detection at 210/254nm showed complete inversion and esterification with 21% (R)-(+)-10,11-dihydro-10-nicotinoyioxy-5H-dibenz/b,f/azepine-5-carboxamide with retention time of 22.31 minutes and 75% (S)-(-)-10,11-dihydro-10-nicotinoyloxy-5H- dibenz/b,f/azepine-5-carboxamide with retention time of 28.4 minutes.
Example 5. (R)-(+)-10-Acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (Vl)
To a stirred suspension of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5- carboxamide (II) (1.0g, 3.94mmol) (99.4% optical purity by chiral HPLC analysis), triphenylphosphine (1.03g, 3.94mmol) and acetic acid (0.47g, 7.88mmol) in tetrahydrofuran (12mL) cooled in an ice-water bath was added diisopropylazodicarboxylate (0.8Og, 3.94mmol) dropwise. After addition was complete, the reaction mixture, which became a cloudy yellow solution was allowed to stir at room temperature for four hours, whereupon the tetrahydrofuran was evaporated (4O0C, water-aspirator pressure), lsopropanol (5mL) was added to the oily residue and the mixture was warmed to the boiling point of the solvent. The mixture was then allowed to cool to room temperature, and then stored at 50C for one hour. The precipitate was collected by filtration, and then recrystallised from isopropanol (4 mL). The crystals were collected by filtration and after drying to constant weight, there was obtained (R)- (+)-10-acetoxy-10,11-dihydro-5H-dibenz/b,f/azepine-5-carboxamide (V) as white crystals (0.47g, 40%) of m.p. 186-1870C.
Chiral HPLC analysis of this product (LiChroCART 250-4 HPLC Cartridge ChiraDex 5μm, (Merck), Flowrate: O.δmL/min, Mobile Phase: 0.1 M Na2HPO4 buffer pH7/methanol
88:12, sample injected was 20μL of 0.2mg analyte/mL dissolved in the mobile phase, and UV detection at 210/254nm showed complete inversion and O-acetylation with
99.5% (RX+J-IO-acetoxy-IO.I I-dihydro-δH-dibenz/b.f/azepine-δ-carboxamide (Vl) with retention time 15.98 minutes and 0.5% (S)-(-)-10-acetoxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide (V) with retention time of 21.33 minutes. In this specification, the expression "optically pure" is used to include compositions which have optical purity of at least 80%, preferably at least 90%, most preferably at least 95%. The upper limit on optical purity may be, for example, 100% or 99.5% or 99%. The expression "optically enriched" means that there is more of one stereoisomer than there is of another stereoisomer in the composition, and, in particular, preferably means that there is at least at least 1 % more of one stereoisomer (the "optically enriched" stereoisomer) than there is of the other stereoisomer, i.e., that there is at least 50.5% of the "optically enriched" stereoisomer and up to 49.5% of the other stereoisomer.
It will be appreciated that the invention described above may be modified.

Claims

Claims
1. A method for the chiral inversion and esterification of optically pure or optically enriched (R)-(-)-10,11-dihyclro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) 5 comprising reacting optically pure or optically enriched (R)-(-)-10,11-dihydro-10- hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) with a carboxylic acid nucleophile in the presence of a trisubstituted phosphine and a disubstituted azodicarboxylate in a substantially inert solvent.
2. A method for the chiral inversion and esterification of optically pure or optically enriched (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) comprising reacting optically pure or optically enriched (S)-(+)-10,11-dihydro-10- hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) with a carboxylic acid nucleophile in the presence of a trisubstituted phosphine and a disubstituted azodicarboxylate in a substantially inert solvent.
3. A method according to claim 1 or 2 wherein the carboxylic acid nucleophile is an aliphatic carboxylic acid, straight or branched, containing from one to eighteen carbon atoms, optionally substituted by an aryl group or halogen wherein the term halogen means fluorine, chlorine, bromine or iodine.
4. A method according to claims 1 , 2 or 3 wherein the carboxylic acid nucleophile is acetic acid.
5. A method according to claim 1 or 2 wherein the carboxylic acid nucleophile is an cyclic acid containing from four to seven carbon atoms.
6. A method according to claim 1 or 2 wherein the carboxylic acid nucleophile is benzoic acid, optionally substituted by alkoxy, halogen or nitro groups.
7. A method according to claim 1 or 2 wherein the carboxylic acid nucleophile is a heteroaromatic acid containing at least one atom of nitrogen.
8. A method according to claim 1 or 2 wherein the tri-substituted phosphine is chosen from tri-n-propylphosphine, tri-n-butylphosphine, triphenylphosphine, tri-o- tolylphosphine, diphenyl(2-pyridyl)phosphine, (4-dimethylamino)diphenylphosphine and tris(dimethylamino)phosphine.
5
9. A method according to claim 1 or 2 wherein the disubstituted azodicarboxylate is chosen from dimethylazodicarboxylate, diethylazodicarboxyiate, diisopropylazodicarboxylate, di-tert-butylazodicarboxylate and 1,1 '- (azodicarbonyl)dipiperidine.
10
10. A method according to claim 1 or 2 wherein the substantially inert solvent is chosen from dichloromethane, chloroform, carbon tetrachloride, tetrahydrofuran, diethyl ether, dimethylformamide, dioxane and toluene.
15 11. A method for the preparation of a compound of general formula (VIII):
Figure imgf000015_0001
0 where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting (R)-(-)-10,11-dihydro-10- hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) by a method according to claim 1.
12. A method according to claim 11, wherein the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 8 carbon atoms.
13. A method according to claim 11, wherein the term alkyl means a straight or 5 branched hydrocarbon chain containing from 1 to 4 carbon atoms.
14. A method according to claim 11, 12 or 13, wherein the term cycloalkyl means an alicyclic saturated group with 5 or 6 carbon atoms.
15. A method for the preparation of a compound of general formula (IX):
Figure imgf000016_0001
(IX) where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, aryl or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group, said method comprising reacting (S)-(+)-10,11-dihydro-10- hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) by a method according to claim 2.
16. A method according to claim 15, wherein the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 8 carbon atoms.
17. A method according to claim 15, wherein the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 4 carbon atoms.
18. A method according to claim 15, 16 or 17, wherein the term cycloalkyl means an alicyclic saturated group with 5 or 6 carbon atoms.
19. A method for the preparation of (S)-(-)-10-acetoxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide (V) comprising reacting optically pure or optically enriched (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II) by a method according to claim 1.
20. A method for the preparation of (R)-(+)-iO-acetoxy-10,11-dihydro-5H- dibenz/b,f/azepine-5-carboxamide (Vl) comprising reacting optically pure or optically enriched (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) by a method according to claim 2.
21. A method substantially as herein described, with reference to the examples.
PCT/GB2005/002744 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof WO2006005951A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA2574002A CA2574002C (en) 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
EP05759707A EP1789395B8 (en) 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
BRPI0513383-1A BRPI0513383A (en) 2004-07-13 2005-07-13 methods for chiral inversion and esterification of a compound and for the preparation of a compound
DE602005012405T DE602005012405D1 (en) 2004-07-13 2005-07-13 METHOD FOR THE CHIRAL INVERSION OF (S) - (+) - AND (R) - (-) - 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ / B, F / AZEPIN-5-CARBOXYLIC ACID AND OPTICALLY ENRICHED MIXTURES THEREOF
AU2005261497A AU2005261497A1 (en) 2004-07-13 2005-07-13 Method for chiral inversion of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
DK05759707T DK1789395T3 (en) 2004-07-13 2005-07-13 Process for chiral inversion of (S) - (+) - and (R) - (-) - 10,11-dihydro-10-hydroxy-5H-dibenz [b, f] azepine-5-carboxamide and optically enriched mixtures thereof
MX2007000575A MX2007000575A (en) 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10, 11-dihydro-10- hydroxy-5h -dibenz/b, f/azepine-5 -carboxamide and optically enriched mixtures thereof.
JP2007520888A JP2008506676A (en) 2004-07-13 2005-07-13 (S)-(+)-, and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz / b, f / azepine-5-carboxamide, and optically concentrated mixtures thereof are chiral. How to flip
US11/572,077 US7999100B2 (en) 2004-07-13 2005-07-13 Method for chiral inversion of (S)-(+)-and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
PL05759707T PL1789395T3 (en) 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
HR20090212T HRP20090212T1 (en) 2004-07-13 2009-04-08 Method for chiral inversion (s)-(+)- and (r)-(-)10,11 dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0415664.2 2004-07-13
GB0415664A GB2416167A (en) 2004-07-13 2004-07-13 Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides

Publications (1)

Publication Number Publication Date
WO2006005951A1 true WO2006005951A1 (en) 2006-01-19

Family

ID=32893499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/002744 WO2006005951A1 (en) 2004-07-13 2005-07-13 Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof

Country Status (20)

Country Link
US (1) US7999100B2 (en)
EP (1) EP1789395B8 (en)
JP (1) JP2008506676A (en)
CN (1) CN100582095C (en)
AR (1) AR050170A1 (en)
AT (1) ATE420864T1 (en)
AU (1) AU2005261497A1 (en)
BR (1) BRPI0513383A (en)
CA (1) CA2574002C (en)
DE (1) DE602005012405D1 (en)
DK (1) DK1789395T3 (en)
ES (1) ES2320155T3 (en)
GB (1) GB2416167A (en)
HR (1) HRP20090212T1 (en)
MX (1) MX2007000575A (en)
PL (1) PL1789395T3 (en)
PT (1) PT103308B (en)
RU (1) RU2382772C2 (en)
SI (1) SI1789395T1 (en)
WO (1) WO2006005951A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010113179A3 (en) * 2009-04-02 2011-01-27 Glenmark Generics Limited Process for purifying eslicarbazepine acetate
WO2011045648A3 (en) * 2009-10-12 2011-06-09 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
WO2011091131A2 (en) * 2010-01-23 2011-07-28 Dr. Reddy's Laboratories Ltd. Eslicarbazepine acetate and its polymorphs
WO2012156987A2 (en) * 2011-05-19 2012-11-22 Glenmark Generics Limited A novel process for the preparation of eslicarbazepine
WO2013008194A2 (en) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2014049550A1 (en) 2012-09-26 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9206135B2 (en) 2005-07-29 2015-12-08 Bial-Portela & Ca, S.A. Asymmetric catalytic reduction of oxcarbazepine
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
US9855277B2 (en) 2009-07-27 2018-01-02 Bial—Portela & Ca, S.A. Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2437078A (en) * 2006-04-11 2007-10-17 Portela & Ca Sa 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives
WO2011117885A1 (en) * 2010-03-23 2011-09-29 Intas Pharmaceuticals Limited Process for preparation of enantiomers of licarbazepine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092572A1 (en) * 2001-05-11 2002-11-21 Portela & Ca Sa Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT101732B (en) * 1995-06-30 1997-12-31 Portela & Ca Sa SUBSTITUTED AZEPINES PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITIONS CONTAINED THEREOF AND USES OF THE NEW COMPOUNDS IN THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS EMPLOYED IN DISEASES OF THE NERVOUS SYSTEM

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092572A1 (en) * 2001-05-11 2002-11-21 Portela & Ca Sa Method for preparation of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CID J ET AL: "Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H- dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT2A/2C receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 11, 7 June 2004 (2004-06-07), pages 2765 - 2771, XP004841284, ISSN: 0960-894X *
MITSUNOBU O: "The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products", SYNTHESIS, THIEME, STUTTGART, DE, 1981, pages 1 - 28, XP002123593, ISSN: 0039-7881 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643929B2 (en) 2005-07-29 2017-05-09 Bial—Portela & Ca, S.A. Asymmetric catalytic reduction of oxcarbazepine
US9206135B2 (en) 2005-07-29 2015-12-08 Bial-Portela & Ca, S.A. Asymmetric catalytic reduction of oxcarbazepine
US9763954B2 (en) 2007-01-15 2017-09-19 Bial—Portela & Ca, S.A. Therapeutical uses of eslicarbazepine
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US10912781B2 (en) 2007-10-26 2021-02-09 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US9566244B2 (en) 2007-10-26 2017-02-14 Bial-Portele & Ca, S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2010113179A3 (en) * 2009-04-02 2011-01-27 Glenmark Generics Limited Process for purifying eslicarbazepine acetate
US9855277B2 (en) 2009-07-27 2018-01-02 Bial—Portela & Ca, S.A. Use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia
WO2011045648A3 (en) * 2009-10-12 2011-06-09 Matrix Laboratories Limited Process for preparing (s)-(-)-10-acetoxy-10,11-dihydro-5h-dibenz[b,f]azepine-5-carboxamide and its esters thereof
WO2011091131A3 (en) * 2010-01-23 2011-12-22 Dr. Reddy's Laboratories Ltd. Eslicarbazepine acetate and its polymorphs
WO2011091131A2 (en) * 2010-01-23 2011-07-28 Dr. Reddy's Laboratories Ltd. Eslicarbazepine acetate and its polymorphs
US9346760B2 (en) 2011-03-08 2016-05-24 Jubilant Life Sciences Limited Process for the preparation of (S)-(+)- or (R)-(-)-10-hydroxy dihydrodibenz[B,F]azepines by enantioselective reduction of 10,11-dihydro-10-OXO-5H-dibenz[B,F]azepines and polymorphs thereof
WO2012156987A2 (en) * 2011-05-19 2012-11-22 Glenmark Generics Limited A novel process for the preparation of eslicarbazepine
WO2012156987A3 (en) * 2011-05-19 2013-03-21 Glenmark Generics Limited Novel process for preparation of eslicarbazepine
WO2013008194A2 (en) 2011-07-13 2013-01-17 Ranbaxy Laboratories Limited Process for the preparation and purification of eslicarbazepine acetate and intermediates thereof
WO2014049550A1 (en) 2012-09-26 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of oxcarbazepine and its use as intermediate in the preparation of eslicarbazepine acetate
US9845293B2 (en) 2015-03-06 2017-12-19 F.I.S.—Fabbrica Italiana Sintetici S.p.A. Process for the preparation of eslicarbazepine and eslicarbazepine acetate
WO2016142164A1 (en) 2015-03-06 2016-09-15 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate
EP3064490A1 (en) 2015-03-06 2016-09-07 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Improved process for the preparation of eslicarbazepine and eslicarbazepine acetate

Also Published As

Publication number Publication date
BRPI0513383A (en) 2008-05-06
SI1789395T1 (en) 2009-06-30
PT103308B (en) 2008-06-11
US7999100B2 (en) 2011-08-16
CA2574002A1 (en) 2006-01-19
GB0415664D0 (en) 2004-08-18
US20080293934A1 (en) 2008-11-27
EP1789395B8 (en) 2009-08-12
PT103308A (en) 2007-01-31
EP1789395B1 (en) 2009-01-14
AU2005261497A1 (en) 2006-01-19
AR050170A1 (en) 2006-10-04
ATE420864T1 (en) 2009-01-15
HRP20090212T1 (en) 2009-09-30
MX2007000575A (en) 2007-03-30
CN101023061A (en) 2007-08-22
EP1789395A1 (en) 2007-05-30
ES2320155T3 (en) 2009-05-19
CN100582095C (en) 2010-01-20
DK1789395T3 (en) 2009-04-20
DE602005012405D1 (en) 2009-03-05
JP2008506676A (en) 2008-03-06
PL1789395T3 (en) 2009-06-30
RU2382772C2 (en) 2010-02-27
CA2574002C (en) 2014-02-04
RU2007105228A (en) 2008-08-20
GB2416167A (en) 2006-01-18

Similar Documents

Publication Publication Date Title
EP1789395B8 (en) Method for chiral inversion of (s)-(+)- and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof
US7820813B2 (en) Method for preparation of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide
US8367821B2 (en) Preparation of eslicarbazepine and related compounds by asymmetric hydrogenation
AU2002253397A1 (en) Method for preparation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide
US7189846B2 (en) Method for racemization of (S)-(+)- and (R)-(−)-10,11-dihydro-10-hydroxy-5h-dibenz[B,F]azepine-5-carboxamide and optically enriched mixtures thereof
KR20070032370A (en) Method for chiral inversion of S-+- and R---10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide and optically enriched mixtures thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2007520888

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000575

Country of ref document: MX

Ref document number: 2005261497

Country of ref document: AU

Ref document number: 2574002

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 908/DELNP/2007

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2005261497

Country of ref document: AU

Date of ref document: 20050713

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005261497

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077003240

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2007105228

Country of ref document: RU

Ref document number: 2005759707

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200580030684.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020077003240

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005759707

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11572077

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0513383

Country of ref document: BR